<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146156</url>
  </required_header>
  <id_info>
    <org_study_id>IRB16-00553</org_study_id>
    <secondary_id>R01HD088061</secondary_id>
    <nct_id>NCT03146156</nct_id>
  </id_info>
  <brief_title>Lifestyle Intervention in Preparation for Pregnancy (LIPP)</brief_title>
  <official_title>Lifestyle Intervention in Preparation for Pregnancy (LIPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies evaluating lifestyle intervention in obese women during pregnancy have reported
      limited success in decreasing excessive gestational weight gain, and have failed to achieve
      the key outcome of breaking the obesity cycle and reducing neonatal adiposity or birth
      weight. Although some investigators advocate weight loss during pregnancy in obese women,
      these recommendations were based on extrapolation of retrospective epidemiological data. Of
      concern, we reported increased small for gestational age babies and decreased lean body mass
      in neonates of obese women with weight loss or inadequate gestational weight gain. Based on
      our research, optimal outcomes from lifestyle interventions are likely to be temporal and
      therefore must be initiated prior to conception to first improve maternal metabolic function,
      and subsequently, placental/fetal growth. Several large retrospective cohort studies support
      our hypothesis. For example, women who lost weight between pregnancies had fewer large for
      gestational age babies in contrast to women who increased interpregnancy weight. In addition,
      prospective randomized controlled trials have shown that postpartum weight loss is achievable
      without adverse maternal or neonatal outcomes, these studies include women who breastfed.
      Based on these observations, we propose a randomized control trial to determine the effect of
      lifestyle intervention initiated prior to a planned pregnancy on improving neonatal
      metabolism and adiposity. Our over-arching hypothesis is that the maternal pre-pregnancy
      metabolic condition determines the obesogenic in-utero environment, which affects programming
      of placental mitochondrial function and metabolic pathways, promoting lipid accumulation and
      neonatal adiposity. Our rationale is based on the need to establish the most effective time
      to introduce an intervention that will break the obesity cycle in mothers and their children.
      Understanding how pregravid metabolic conditioning improves maternal physiology, and cellular
      and molecular function in pregnancy will provide the empirical data to support the
      intervention. We have a highly successful record of recruiting women who are planning a
      pregnancy, obtaining compliance in longitudinal studies, and in long-term follow-up of
      mothers and their offspring. Lifestyle intervention will be initiated prior to conception to
      decrease maternal body fat, inflammation, insulin resistance, and ?-cell dysfunction. Our
      transdisciplinary team has the required expertise in lifestyle interventions management of
      obesity, and in human physiology that is needed to determine the effects of these
      interventions on maternal metabolism and fetalplacental growth and function. We will recruit
      200 women to pursue the following specific aims:

      Specific Aim 1: To investigate the physiological significance of lifestyle intervention in
      preparation for pregnancy (LIPP) on maternal and neonatal metabolism and adiposity.

      Specific Aim 2: To determine the molecular effects whereby lifestyle intervention initiated
      before pregnancy can improve placental mitochondrial lipid oxidation and accumulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To investigate the physiological significance of lifestyle intervention in
      preparation for pregnancy (LIPP) on maternal and neonatal metabolism and adiposity.

      Introduction/Rationale: Our preliminary data demonstrate that supervised lifestyle
      intervention leads to significant weight loss, improved insulin sensitivity, glucose
      tolerance and incretin secretion, together with healthier cardiovascular and body composition
      outcomes in overweight and obese adults. We expect that timing and implementation of the
      proposed lifestyle intervention will produce similar health benefits in overweight/obese
      women planning a second pregnancy, and lead to greater insulin sensitivity, reduced insulin
      secretion, and less inflammation. These improvements will result in the prevention of excess
      nutrient availability (glucose and lipids) from contributing to excess fetal
      growth/adiposity. The working hypothesis for this Aim is that in contrast to GWG, the
      decreased pre-pregnancy insulin sensitivity in obese mothers accounts for the greatest
      clinical variance in fat accretion in the infant. Although clinically we anticipate a
      decrease in weight and BMI in the LIPP group, the improvement in insulin sensitivity and
      metabolic profile are the key physiological measures related to the primary outcome of
      decreased neonatal adiposity, and not the weight loss per se.

      The rationale is that the optimal time to implement lifestyle intervention that effectively
      improves maternal health at the physiological, cellular and molecular level, and results in
      optimal adiposity in the baby, is prior to pregnancy. Women who lose weight postpartum,
      experience a decrease in neonatal birth weight (primarily adipose tissue) in subsequent
      pregnancy, whereas women who gain weight, experience an increase in neonatal birth weight and
      adiposity. We hypothesize that maternal pre-pregnancy metabolic condition determines the
      obesogenic in- utero environment, which in turn affects placental programming of
      mitochondrial and lipid pathways (Specific Aim 2), and body composition of the baby. An
      additional rationale is that there is a need to understand how improved pregravid metabolic
      condition affects maternal physiological and molecular function. We anticipate that obese
      women who complete the LIPP program will enter pregnancy with improved insulin regulated
      metabolism and reduced insulin resistance, thus facilitating a lower neonatal birth weight
      and adiposity. We will recruit mothers who delivered their first baby at MHMC. We recognize
      that these mothers represent a demographic that has limited access to exercise facilities or
      family support systems that would facilitate free time for exercise. In order to reduce
      barriers to participation, we will conduct the exercise sessions in local Community
      Recreation Centers. The Centers have child care facilities and we will support the cost so
      participants may bring their babies to the LIPP sessions. To further increase participation
      and maximize retention, we will provide transportation to and from the Recreation Centers.
      Support for transportation will be requested from the Cleveland Mt. Sinai Foundation.
      Lifestyle Intervention Weight Loss Phase: The LIPP program is designed to promote weight loss
      that is 5-10% of body weight. The 4-month weight loss phase consists of aerobic exercise
      training with diet and behavioral counseling to induce weight loss as was successfully
      achieved in prior studies. Initially, supervised exercise will be prescribed at 55-60% of
      HRmax and gradually increased so that after 1-2 weeks, the subjects are exercising at 75-85%
      of HRmax (~65-70% VO2max). Supervised exercise will consist of walking/jogging on a treadmill
      and stationary cycling, 3 days/week, 60 min/session (i.e., 500 kcal/session). The women will
      wear heart rate (HR) monitors (Polar Electro, Woodbury, NY) during each exercise session so
      that they have visual feedback of their personalized target heart rate goal. Participants
      will be advised to reduce caloric intake by ~500 kcal/d in order to support their weight loss
      goals. The recommended diet will provide ~55% of calories as carbohydrate, 25% as fat, and
      20% as protein. Participants will be instructed to consume complex carbohydrates and to avoid
      simple sugars. Specific caloric needs will be estimated by indirect calorimetry and a
      sedentary (x1.3) physical activity correction factor. Energy intake will be estimated using
      the food photo diary app, Meal Snap. Digital photography provides an excellent estimate of
      energy intake (67). Participants who do not own a smart phone will have one provided through
      support from the Cleveland Foundation.

      Records covering a 72-hour diet period will be shared with the research team for
      determination of calorie and nutrient intake. Meal Snap has a food database of over 350,000
      items. However, some meals will not be in this database, therefore our Lifestyle Coaches will
      enter all foods eaten into our diet database (NDSR, Minneapolis, MN) to facilitate analysis
      of calorie, and macro/micro nutrient intake. Subjects will generate photos from before and
      after the meal in order to estimate the amount of food that was eaten. Data will be obtained
      at baseline, and at 2-week intervals during the initial 16-week supervised weight loss
      period.

      Lifestyle Intervention - Weight Management/Maintenance: The pre-pregnancy weight management
      program (phase 2A, 2B and 2C) is designed to facilitate personalized weight loss goals using
      lifestyle behaviors that include, exercise, diet and behavioral modification, and is based in
      part on the Look AHEAD trial. The intervention includes a toolbox concept to help meet weight
      loss goals. The Lifestyle Coaches will provide personalized instruction on physical activity/
      exercise - 10,000 steps/day, and the participants will use FitBit Flex (Fitbit.com), to track
      step count and exercise time. During the first phase of weight maintenance (2A) the women
      will attend 2 supervised group sessions/week. These sessions include structured exercise
      (e.g., Zumba, jazzercise, stroller walking), review of dietary photo records, where meals
      have been eaten (home or away; recorded on smart phone app), and behavioral counseling (with
      their Lifestyle Coach). Participants will be encouraged to eat 1,200-1,500 kcal/d (~55%
      carbohydrate, 25% fat, 20% protein) if below 113 kg, or 1,500-1,800 kcal/d if &gt;113 kg.
      Dietary data will be analyzed at 4-week intervals during the weight maintenance period.
      Importantly, to minimize subject burden and to maximize retention and data acquisition, the
      Lifestyle Coach will track calorie intake using the participant's photo diary. Behavioral
      strategies to motivate healthy lifestyle decisions will include: self-monitoring (food,
      activity, and weight, using FitBit online resources), goal setting (steps/day, weight loss),
      stimulus control (i.e., social eating, fast food, sitting vs. standing), problem solving
      (have snacks available, exercise at home), and relapse prevention (i.e., holidays, alcohol,
      fast food, sweets, problem foods, compulsive eating). After 4 months and the desired weight
      loss, subjects move to Phase 2B. During this phase subjects maintain an exercise goal of
      10,000 steps/day, but will be required to attend only 1 supervised session/week. If a subject
      fails to maintain weight loss, defined as weight gain of 3% of current body weight,
      participants will return to Phase 2A for more supervised weight management. Alternatively, if
      weight loss is maintained after 3 months, subjects will progress to Phase 2C until the
      subsequent pregnancy. Phase 2C consists of no supervised exercise sessions. However, the
      subject and Lifestyle Coach will converse weekly by phone to review progress, including
      Fitbit exercise data and diet. Data suggest that weight management programs delivered by
      phone are comparable to clinically delivered programs. During the calls participants will be
      counseled to continue to exercise at the intensity and duration prescribed during Phase 2B.
      They will be provided with language-specific food and exercise log books. These will be used
      to guide calorie intake and will provide another record of compliance. Participants
      randomized to the Control group will receive information on post-pregnancy diet/weight loss
      from the CRU nutritionist as distinct from the LIPP nutritionist (HB) to decrease cross
      contamination between groups. Weight Management during Pregnancy: All LIPP and usual
      care/control groups will be followed by their primary Obstetrical provider. The OB/GYN
      department at MHMC has recently revised its clinical guidelines for the management of the
      overweight/obese women based on the December 2015 ACOG practice bulletin (2). All
      overweight/obese women will be offered nutrition counseling early in pregnancy by a
      registered dietician from the MHMC Nutrition Department with follow-up visits as needed to
      support GWG within the IOM guidelines. Nutritional therapy will consider maternal pregravid
      BMI, ethnic, cultural and social factors in individualizing healthy eating. The electronic
      health record (EPIC) includes a graphic GWG nomogram and so GWG will be monitored at each
      visit. All subjects will be encouraged to increase physical activity for at least 30
      minutes/day (primarily walking). Clinical management such as, ultrasounds to estimate fetal
      growth, and fetal surveillance will be based on the ACOG recommendations. The Lifestyle Coach
      will continue to follow-up only with the LIPP subjects as described in the maintenance phase
      of the research design.

      Metabolic Evaluations Metabolic evaluations will be performed at baseline (3 months ? 2
      weeks) postpartum. Follow-up evaluations will be performed after 4 (+/-2 weeks) and 12 months
      (+/-2 weeks), and then every 6 months (+/-2 weeks) prior to pregnancy up to a maximum of 24
      months. Once a subject has pregnancy dating and viability confirmed by ultrasound, metabolic
      evaluations will continue at 12-16 and 32-36 weeks of gestation.

      Maternal Body Composition: Anthropometry measurements will include height, weight, and hip
      and waist circumferences. Total body fat will be measured by whole body plethysmography (Bod
      Pod; Cosmed, Rome, Italy). We will use a hydration constant of 76% for fat free mass during
      late pregnancy.

      Resting Energy Expenditure: Resting Metabolic Rate (RMR) will be determined after an
      overnight fast using the Cosmed OMNIA metabolic cart (Cosmed, Rome Italy) with a canopy
      system. We will control for diet by providing a standardized energy balanced meal the evening
      prior to the test from the CRU. Participants will relax in a quiet low-light metabolic room
      for 30 min prior to obtaining a 30 min measure of exhaled breath. Oxidative and non-oxidative
      glucose metabolism will be estimated and urine samples will be obtained before and after the
      measure in order to calculate non-protein RQ (NPRQ). These data will be used in conjunction
      with Specific Aim 2, and will be correlated with change in mitochondrial function during
      pregnancy.

      Exercise Capacity: An incremental graded treadmill test will be performed at baseline, 4, and
      6 month time points in both groups. Oxygen consumption (Jaeger OxyCon Pro/Delta System,
      Hoechberg, Germany), heart rate, and ratings of perceived exertion will be performed as
      previously described.

      Insulin Sensitivity and ?-Cell Function: A 75 g oral glucose tolerance test (OGTT) will be
      used to assess postprandial glycemia, and insulin sensitivity and secretion. After an
      overnight fast, blood samples will be drawn at 10 min intervals for the first 60 min, and at
      20 min intervals thereafter. C-peptide data will be analyzed using a combined model approach
      to provide pre-hepatic insulin secretion rates, insulin sensitivity, disposition index, and
      relate insulin and Cpeptide kinetics (73). Plasma glucose will be measured using the glucose
      oxidase method (YSI; Yellow Springs, OH).

      Insulin will be assayed by RIA (Millipore, Billerica, MA). Diagnosis of GDM will be made
      using criteria recommended by the ACOG (74).

      Enteroinsular Axis Responses: Plasma samples (with appropriate additives) will be obtained to
      measure incretin hormones (glucagon-like peptide-1 (GLP-1), and glucose-dependent
      insulinotropic polypeptide (GIP), and satietyrelated gut peptides (cholecystokinin (CCK), and
      peptide YY (PYY). Measurements will be made under static (fasting) and dynamic
      (glucose-stimulated) conditions (10 min intervals up to 1 hour).

      Metabolic and Inflammatory Biomarkers: Fasting blood samples will be obtained to measure CBC,
      TSH, HbA1c, lipid panel, and total free fatty acids (FFA). Adipocytokines (adiponectin,
      leptin interleukin-6, interleukin- 8, TNF-? and hsCRP) will be measured using ELISA (R&amp;D
      Systems, Minneapolis, MN). All samples from each subject will be stored at -80oC and run in
      the same assay at completion to decrease variability.

      Quality of Life Questionnaire: The SF-36 health survey will be used at baseline, 4 and 12
      months, and then at 6 month intervals until pregnancy to assess the subject's health-related
      quality of life. These data will provide a generic measure of physical and mental health
      through assessment of physical functioning, bodily pain, limitations due to physical,
      personal, or emotional problems and well-being, energy/fatigue, and general health
      perceptions. During pregnancy the questionnaire will be administered at 12-16 and 32-36
      weeks.

      Measuring Fat Mass in the Infant: We have extensive experience in estimating body composition
      in neonates, and were one of the first centers to procure a Pea Pod (pediatric air
      densitometry), which is housed in the CRU next to Labor &amp; Delivery and the postpartum unit.

      Insulin Resistance at Birth: At birth we will obtain umbilical cord blood for insulin and
      glucose to estimate insulin resistance using HOMA. Full lipid profile, CRP, and the
      adipokines IL-6 and leptin (an excellent marker of neonatal fat mass) will be measured in
      cord blood as described above.

      Anticipated Results, Challenges, and Alternative Approaches The primary outcome measure of
      this proposal is lower neonatal adiposity at birth in the LIPP group relative to: 1) the
      Control group and 2) with the subject's firstborn. As secondary outcomes we anticipate that
      prior to a subsequent pregnancy, LIPP will produce significant improvement (absolute and
      percent changes) in maternal weight and body composition, and more importantly improved
      insulin sensitivity, beta-cell function, incretin response to glucose, lipid and inflammatory
      biomarkers, compared to the Control group. We also expect reduced insulin resistance, cord
      lipids and inflammatory profiles in babies born to LIPP compared to Controls.

      Recruitment is a well-recognized problem for the successful implementation and completion of
      lifestyle intervention trials. However, given the novel strategy for recruitment detailed
      above, our unique access to the patient population, and our extensive experience in metabolic
      research in pregnancy, we do not anticipate recruitment to present an insurmountable
      challenge. We will recruit 200 subjects in the first 4 years and complete all mother/baby
      evaluations according to the proposed timeline. If necessary we will recruit subjects from
      Cleveland Clinic and University Hospitals, both affiliated with Case Western Reserve
      University (CWRU). Retention strategies include free transportation to the exercise sessions,
      free childcare service during the lifestyle sessions and consults with the Lifestyle Coach,
      cell phone apps to reduce subject burden with data entry, regular telephone contacts, and
      financial incentives, including an infant car seat at delivery.

      Our team has had outstanding success in retaining pregnant women in our previous metabolic
      research and lifestyle intervention studies in overweight and obese populations (48,64). In
      the current proposal, additional strategies are also in place to maximize retention and
      minimize dropout. These include phone calls and emails from the Lifestyle Coach to review and
      reinforce problem solving and self-monitoring skills as described for participants in the
      Diabetes Prevention Program. We will also establish a buddy system where each participant
      becomes a buddy to another participant, the two buddies may prepare meals together, exercise
      together, share problems, etc. The buddy system fosters the sense that staying in the study
      is important not just for the individual's health but also for the buddy's as well. If
      subjects in the LIPP program do not meet their target weight loss goal, we will implement a
      meal replacement strategy using the resources of the CRU/CTSC metabolic kitchen, with
      attention to the caloric and nutrient needs of the mother depending on breast feeding. Not
      all participants will conceive. Since the primary outcome is neonatal adiposity, subjects who
      do not become pregnant will not be included in the primary analysis but will be included in
      secondary analyses relating to pregravid metabolic improvement. By recruiting women with a
      previous pregnancy the risk of infertility is significantly reduced. We anticipate that
      approximately 20% of women will experience a spontaneous abortion, but they will be allowed
      to continue and resume their previous participation in either the LIPP or Control group. We
      anticipate that approximately 25% of subjects will drop out before becoming pregnant, and
      another 15% may drop out during pregnancy. We will enroll 100 subjects in each arm to account
      for the unlikely event of 40% dropout. Adopting an even more stringent strategy, we report
      statistical power is available for as low as 50 subjects per group as a worst-case scenario.
      If retention lags behind projections we will recruit additional subjects at MHMC and CWRU
      affiliated hospitals. The CRU staff will assist in collecting cord blood and placenta at
      delivery and performing the Pea Pod body measures. If there is a Pea Pod equipment
      malfunction we will estimate body composition using neonatal anthropometrics.

      Although LIPP subjects will be encouraged to delay a second pregnancy until they are in the
      maintenance phase of the program, we will exclude LIPP subjects only if they conceive during
      the first 4 month weight loss phase. For the Control subjects, exclusion will occur if a
      subject becomes pregnant before the 3 month postpartum CRU randomization visit. Use of birth
      control in this phase is an inclusion criterion. Not all LIPP subjects will conceive at
      similar times after the 4 month weight loss intervention. We will not adjust for the time
      between pregnancies between the LIPP and Control subjects. We will use the LIPP and control
      subject's metabolic status (body composition, insulin sensitivity and response, etc.) at the
      last metabolic evaluation in the CRU before becoming pregnant as their pregravid or baseline
      status for the subsequent pregnancy. Because this is a pregnancy study only women with be
      recruited. However, we will assess the effect of LIPP on males and female offspring, together
      and independently, based on sex.

      Statistical Approach The primary analyses of Specific Aim 1a will be intent-to-treat
      comparisons of the LIPP and Control groups in regard to changes in maternal insulin
      sensitivity, BMI, and fat mass. The comparisons will be performed first with two-sample
      t-tests at p=0.05. Should any imbalance of confounding factors in the groups be recognized,
      linear regression models that include significant differences (e.g. GDM) will be used to
      perform covariate adjustments. Based on our 1 year postpartum follow-up studies (62,63), we
      will have 90% power to detect an absolute or covariate-adjusted improvement in insulin
      sensitivity of 30% and an 80% power to detect an improvement as small as 25% in the LIPP vs.
      Control group. Corresponding 95% confidence intervals (95% CI) for the absolute or
      covariate-adjusted differences or percent improvements in insulin sensitivity between groups
      will be reported. We estimate the standard deviation (SD) of change in BMI from randomization
      until subsequent pregnancy to be 5.1 kg/m2. We will have 90% power to detect an absolute or
      covariate-adjusted difference in BMI of 2.6 kg/m2 and 80% power to detect a difference of
      2.26 kg/m2 and 90% power to detect an absolute or covariate-adjusted difference in fat mass
      of 5.9 kg and 80% power to detect a difference of 5.1 kg between groups prior to the second
      pregnancy. The primary analysis for Specific Aim 1b is an intent-to-treat comparison of LIPP
      versus Control neonates with respect to fat mass at birth. The comparison will be performed
      using a two-sample t-test at p=0.05. Linear regression will be performed, which will include
      weight (body composition measures) of the subject's first child as a covariate. Should any
      imbalance of confounding factors (for example gestational age) in the groups be recognized,
      linear regression models will be used to perform a covariate adjustment. Based on our
      preliminary data, we estimate the SD of neonatal fat mass between the LIPP and Control groups
      to be no more than 225g. With at least 50 women in each group, (assuming a 50% dropout), the
      t-test or linear regression will have 90% power to detect an absolute or covariate-adjusted
      difference of 146 g fat mass between groups. We have 80% power to detect an absolute or
      covariate-adjusted difference as small as 126 g fat mass between groups. Corresponding 95% CI
      for the absolute or covariate-adjusted difference in neonatal fat mass between groups will be
      reported. For secondary analyses, we will be using the same statistical approach. Based on
      our preliminary data, we estimate the SD of birth weight to be 700 g; with 50 neonates in
      each group we will have 90% power to detect an absolute or covariate-adjusted difference of
      455 g in birth weight and 80% power to detect a 393 g difference between groups. Additional
      secondary analyses will include umbilical cord cytokines. Comparisons will be performed using
      a two-sample t-test at a significance level of p=0.05; however, Mann- Whitney U tests or log
      transformations will be employed if data are not normally distributed. Linear regression
      models, including confounding factors, will be used to perform covariate adjustments. Based
      on our published data (80), we estimate the standard deviations of umbilical cord IL-6 and
      CRP to be 3.4 pg/ml and 7,900 ng/ml, respectively. With 50 women in each group, we will have
      90% power to detect an improvement in IL-6 and CRP levels of 50% and 42%, and 80% power to
      detect an improvement of 42% and 36%, respectively.

      Specific Aim 2: To determine the molecular effects whereby lifestyle intervention initiated
      before pregnancy can improve placental mitochondrial lipid oxidation and accumulation.

      Introduction/Rationale: Our data suggest that in obese women, a mitochondrial defect in
      placental tissue is present early in pregnancy, inhibiting the placental capacity for fatty
      acid oxidation and shunting fatty acids to esterification pathways and lipid accumulation,
      potentially leading to increased nutrient availability to the fetus and higher adiposity at
      term. Our group has shown that other mitochondrial processes, such as cholesterol transport
      and steroidogenesis are impaired in placentas of obese, insulin resistant women at term.
      Placental mitochondrial content (assessed by mtDNA and citrate synthase activity) is not
      affected by maternal obesity and insulin resistance at term, suggesting that the observed
      defects in function are due to changes in mitochondrial activity, rather than number.
      Previous dietary interventions initiated during pregnancy were unable to alter placental
      ?-oxidation or fetal fat deposition, potentially because the intervention was begun after
      placental mitochondrial function was impaired. We anticipate that LIPP will improve placental
      mitochondrial fatty acid oxidation, which will be measurable at term and associated with
      lower fatty acid esterification and accumulation, and neonatal fat mass. The hypothesis is
      that the decreased insulin sensitivity and increased inflammatory environment in obese
      mothers impairs mitochondrial ?-oxidation in the developing placenta. It is the changes in
      placental metabolism beginning early in pregnancy that lead to altered nutrient delivery and
      increased fetal fat deposition. Our rationale is based on the need to understand how changes
      in placental lipid metabolism mediate the effects of improved pregravid metabolism on
      neonatal adiposity. We expect that placentas of obese women in the LIPP program will show
      improved fatty acid oxidation and decreased lipid esterification and accumulation at term.
      Furthermore, we expect that these changes will correlate with lower maternal inflammation and
      insulin resistance in early pregnancy and lower neonatal adiposity at term.

      Anticipated Results and Endpoints: We anticipate that compared to the Control group,
      placentas of women in LIPP will have: 1) increased ?-oxidation, 2) decreased fatty acid
      esterification, 3) lower lipid content, 4) increased activity of mitochondrial CPT1B, the
      rate-limiting enzyme in ?-oxidation, and higher phosphor ACC, which, when phosphorylated,
      produces less malonyl CoA, the main inhibitory regulator of CPT1B, and 5) no difference in
      mitochondrial content (as measured by mtDNA and citrate synthase activity). We also
      anticipate that mitochondrial ?-oxidation and CPT1B activity will negatively correlate with
      early pregnancy maternal serum inflammatory cytokine markers and insulin resistance and
      neonatal adiposity.

      Experimental Design: We will accomplish the objectives of Specific Aim 2 by measuring changes
      in placental mitochondrial enzyme activity and lipid metabolism in women enrolled in the
      Control or LIPP groups described in Specific Aim 1. Placental tissue will be collected at
      delivery from all study participants and embedded in paraffin, or snap frozen in liquid
      nitrogen, and stored at -80oC for molecular analysis. In a subset of women delivering by
      scheduled Cesarean delivery (we estimate ~30% of our participants or N=15-18/group), we will
      also collect fresh placental tissue for lipid metabolism activity assays.

      Placental lipid metabolism: These assays are well established in the O'Tierney-Ginn lab.
      Mitochondrial fatty acid oxidation (FAO) and esterification into total lipid assays will be
      performed in placental explants as described previously, with some modifications. Freshly
      isolated placental explants will be incubated in the presence of 100 ?M cold palmitate and
      3H-palmitate (Moravek Radiochemicals) for 18 hrs. At the end of the incubation period, media
      will be collected to quantify the FAO rate by detection of 3H2O using the vapor phase
      equilibration method of Hughes. Esterificationinto total lipids will be determined by
      homogenizing the treated explants in HPLC-grade acetone and incubating with agitation at room
      temperature overnight. An aliquot of the acetone-extract lipid suspension will be used to
      determine the radioactive content by liquid scintillation counting. Oxidation and
      esterification rates will be defined as nmol palmitate/mg tissue/hr.

      Assessment of placental mitochondria: Mitochondria will be isolated from frozen placental
      tissue as previously described. Markers of lipid oxidation (CPT1B) and
      synthesis/esterification (phospho-ACC) activity will be measured using commercially available
      kits (Cell Signaling, Abcam) in isolated mitochondria from all samples. Markers of
      mitochondrial content (mtDNA and citrate synthase activity) will be measured in whole
      placental tissue in all samples as previously described.

      Placental Lipid Accumulation: Total placental lipid content will be measured using the Folch
      method.

      Anticipated Challenges and Alternatives: 1) We will use only placentas delivered by scheduled
      cesarean delivery for in vitro oxidation and esterification assays, to avoid changes
      pertinent to labor. At our hospital, the rate of cesarean for obese women is ~40%. Our
      conservative estimate of 40-50% drop-out followed by 30% of subjects delivering by cesarean,
      results in N=15-18/group. Based on our preliminary data, this will leave us adequately
      powered to detect differences in placental lipid metabolism due to LIPP. We will collect
      placental samples from all study participants for mitochondrial enzyme activity assays,
      providing us with an additional assessment of metabolic activity in a larger number of
      participants. 2) Placental mitochondrial fatty acid oxidation capacity may be affected by
      mitochondrial number, oxidative phosphorylation activity, and energetic efficiency
      (coupling). Assessment of mitochondrial oxidative phosphorylation capacity or energetic
      efficiency requires freshly isolated mitochondria and/or living cells which, for our
      proposal, would be overly ambitious and costly considering the unpredictable nature of
      delivery and the large number of participants. Alternatively, we will measure markers of
      mitochondrial content and key enzymes in mitochondrial lipid metabolism in all placental
      samples to assess some potential mechanisms underlying changes in placental fatty acid
      oxidation. Additionally, frozen samples collected from all placentas can be used to measure
      enzymes involved in electron transport (e.g., ATP synthase) as a marker of mitochondrial
      oxidative phosphorylation.

      Statistical Analysis: The primary goal of Aim 2 is to determine the effect of lifestyle
      intervention prior to pregnancy on placental mitochondrial fatty acid oxidation at term. We
      hypothesize that placental ?-oxidation will be higher in the LIPP group. We will conduct an
      intent-to-treat analysis using two sample t-test or non-parametric Wilcoxon rank-sum test to
      assess differences between groups. Regression analysis will be used to assess the association
      of placental ?-oxidation and enzyme activity with maternal inflammatory cytokine levels and
      insulin resistance in early pregnancy, along with neonatal fat mass with adjustment for
      gestational age and gender. Descriptive statistics, such as mean, median and range will be
      calculated for all variables. Power and sample size analysis based on our preliminary
      mitochondrial ?- oxidation data in obese women (38?14 nmol/mg/hr) showed that a sample size
      of N=18/group achieves 80% power to detect a difference of 25% between groups using a
      two-sample t-test with a significance level of 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal adiposity comparison between intervention and usual care group</measure>
    <time_frame>48 to 72 hours after delivery</time_frame>
    <description>Neonatal anthropometry and air densitometry (pea pod)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal metabolic status</measure>
    <time_frame>from baseline to 6 month post-partum and then during pregnancy at 12 to 16 weeks gestation and 34 to 36 weeks gestation.</time_frame>
    <description>body composition, insulin sensitivity and insulin response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obesity</condition>
  <condition>Lifestyle-related Condition</condition>
  <condition>Macrosomia, Fetal</condition>
  <arm_group>
    <arm_group_label>Lifestyle Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Intervention</intervention_name>
    <description>The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.</description>
    <arm_group_label>Lifestyle Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        All subjects will have had by the time of randomization at 3 months postpartum:

          1. Planning another pregnancy within the next 24 months

          2. Planning to deliver at Tufts medical center during their next pregnancy

          3. A previous full-term singleton pregnancy (gestational age &gt; 37 weeks)

          4. 18 to 40 years of age at the time of enrollment into the study

          5. Vaginal or cesarean delivery

          6. Normal glucose tolerance or gestational diabetes (GDM), but without evidence of
             postpartum diabetes as defined by a 75 g 2-hr oral glucose tolerance test (OGTT)

          7. Normal blood pressure or mild preeclampsia but normal postpartum blood pressure

          8. Bottle or breast feeding

          9. Normal thyroid function (determined by TSH concentration in blood), normal cell blood
             count and normal kidney and liver functions. Lipid profile with triglyceride levels
             not higher than 400 mg/dl (fasting) and LDL levels less than 180 mg/dL

         10. No clinical signs or symptoms of cardiovascular disease or any other disease or
             condition that may contraindicate participation in exercise training (i.e. COPD,
             severe asthma, orthopedic abnormalities)

         11. Using contraception

        Exclusion criteria:

          1. Pre or post-delivery diabetes

          2. Post-delivery hypertension requiring medication

          3. asthma requiring more than occasional use of a sympathomimetic inhaler, but not
             chronic inhaled steroids

          4. Inflammatory bowel disease

          5. Need for assisted reproductive technologies to become pregnant

          6. Medical or obstetrical contraindication to the defined exercise program or diet

          7. Tobacco, excessive alcohol use (greater than 2 drinks/day) or illicit drug use

          8. Eating disorders such as bulimia

          9. Gastric surgery to lose weight including banding or bypass procedures

         10. Any psychological or psychiatric condition which may impair participation in the
             lifestyle intervention program

         11. Multiple pregnancy

         12. HIV, or hepatitis B or C

         13. If a LIPP subject becomes pregnant prior to 16 weeks after randomization before the
             weight- loss phase for the lifestyle intervention is completed or a control subject
             becomes pregnant before the 3 month postpartum randomization, i.e. no baseline
             measurement.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>We will recruit a total of 200 overweight/obese subjects (defined as pregravid BMI 25-35 kg/m2) at the time of their first pregnancy, hereafter defined as obese for the purposes of the proposal) determined by review of the electronic medical record (EMR) after delivery of their first child.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larraine Presley, MS, RN</last_name>
    <role>Study Director</role>
    <affiliation>Metro Health, Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Axelrod, MS</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick M Catalano, MD</last_name>
    <phone>617-636-1468</phone>
    <email>pcatalano@tuftsmedicalcenter.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John P Kirwan, PhD</last_name>
    <email>John.Kirwan@pbrc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P Kirwan, PhD</last_name>
      <email>John.Kirwan@pbrc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chris Axelrod, M.Ed</last_name>
      <email>Christopher.Axelrod@pbrc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Catalano, MD</last_name>
      <phone>617-636-1468</phone>
    </contact>
    <contact_backup>
      <last_name>Kate Russell</last_name>
      <phone>617-636-9197</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Bryant Mantha, MD</last_name>
      <phone>617-724-0138</phone>
      <email>abryant@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, de Las Fuentes L, He S, Okunade AL, Patterson BW, Klein S. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016 Apr 12;23(4):591-601. doi: 10.1016/j.cmet.2016.02.005. Epub 2016 Feb 22.</citation>
    <PMID>26916363</PMID>
  </reference>
  <reference>
    <citation>ACOG Practice Bulletin No 156: Obesity in Pregnancy. Obstet Gynecol. 2015 Dec;126(6):e112-26. doi: 10.1097/AOG.0000000000001211. Erratum in: Obstet Gynecol. 2016 Dec;128(6):1450.</citation>
    <PMID>26595582</PMID>
  </reference>
  <reference>
    <citation>Finer LB, Zolna MR. Declines in Unintended Pregnancy in the United States, 2008-2011. N Engl J Med. 2016 Mar 3;374(9):843-52. doi: 10.1056/NEJMsa1506575.</citation>
    <PMID>26962904</PMID>
  </reference>
  <reference>
    <citation>Catalano PM. Increasing maternal obesity and weight gain during pregnancy: the obstetric problems of plentitude. Obstet Gynecol. 2007 Oct;110(4):743-4.</citation>
    <PMID>17906003</PMID>
  </reference>
  <reference>
    <citation>Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012 Feb 1;307(5):491-7. doi: 10.1001/jama.2012.39. Epub 2012 Jan 17.</citation>
    <PMID>22253363</PMID>
  </reference>
  <reference>
    <citation>Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012 Feb 1;307(5):483-90. doi: 10.1001/jama.2012.40. Epub 2012 Jan 17.</citation>
    <PMID>22253364</PMID>
  </reference>
  <reference>
    <citation>Ananth CV, Wen SW. Trends in fetal growth among singleton gestations in the United States and Canada, 1985 through 1998. Semin Perinatol. 2002 Aug;26(4):260-7.</citation>
    <PMID>12211616</PMID>
  </reference>
  <reference>
    <citation>Surkan PJ, Hsieh CC, Johansson AL, Dickman PW, Cnattingius S. Reasons for increasing trends in large for gestational age births. Obstet Gynecol. 2004 Oct;104(4):720-6.</citation>
    <PMID>15458892</PMID>
  </reference>
  <reference>
    <citation>Catalano PM. Management of obesity in pregnancy. Obstet Gynecol. 2007 Feb;109(2 Pt 1):419-33. Review.</citation>
    <PMID>17267845</PMID>
  </reference>
  <reference>
    <citation>Donahue SM, Kleinman KP, Gillman MW, Oken E. Trends in birth weight and gestational length among singleton term births in the United States: 1990-2005. Obstet Gynecol. 2010 Feb;115(2 Pt 1):357-64. doi: 10.1097/AOG.0b013e3181cbd5f5.</citation>
    <PMID>20093911</PMID>
  </reference>
  <reference>
    <citation>Gibson KS, Waters TP, Gunzler DD, Catalano PM. A retrospective cohort study of factors relating to the longitudinal change in birth weight. BMC Pregnancy Childbirth. 2015 Dec 22;15:344. doi: 10.1186/s12884-015-0777-8.</citation>
    <PMID>26693917</PMID>
  </reference>
  <reference>
    <citation>Rasmussen KM, Abrams B, Bodnar LM, Butte NF, Catalano PM, Maria Siega-Riz A. Recommendations for weight gain during pregnancy in the context of the obesity epidemic. Obstet Gynecol. 2010 Nov;116(5):1191-5. doi: 10.1097/AOG.0b013e3181f60da7. Review.</citation>
    <PMID>20966705</PMID>
  </reference>
  <reference>
    <citation>Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics. 2004 Jul;114(1):e29-36.</citation>
    <PMID>15231970</PMID>
  </reference>
  <reference>
    <citation>Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005 Mar;115(3):e290-6.</citation>
    <PMID>15741354</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, de Mouzon SH, Amini SB. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr. 2009 Nov;90(5):1303-13. doi: 10.3945/ajcn.2008.27416. Epub 2009 Sep 16.</citation>
    <PMID>19759171</PMID>
  </reference>
  <reference>
    <citation>Philipps LH, Santhakumaran S, Gale C, Prior E, Logan KM, Hyde MJ, Modi N. The diabetic pregnancy and offspring BMI in childhood: a systematic review and meta-analysis. Diabetologia. 2011 Aug;54(8):1957-66. doi: 10.1007/s00125-011-2180-y. Epub 2011 May 31. Review.</citation>
    <PMID>21626451</PMID>
  </reference>
  <reference>
    <citation>Walsh JM, McGowan CA, Mahony R, Foley ME, McAuliffe FM. Low glycaemic index diet in pregnancy to prevent macrosomia (ROLO study): randomised control trial. BMJ. 2012 Aug 30;345:e5605. doi: 10.1136/bmj.e5605.</citation>
    <PMID>22936795</PMID>
  </reference>
  <reference>
    <citation>Vinter CA, Jensen DM, Ovesen P, Beck-Nielsen H, Jrgensen JS. The LiP (Lifestyle in Pregnancy) study: a randomized controlled trial of lifestyle intervention in 360 obese pregnant women. Diabetes Care. 2011 Dec;34(12):2502-7. doi: 10.2337/dc11-1150. Epub 2011 Oct 4.</citation>
    <PMID>21972411</PMID>
  </reference>
  <reference>
    <citation>Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, Crowther CA, Wittert G, Owens JA, Robinson JS; LIMIT Randomised Trial Group. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. BMJ. 2014 Feb 10;348:g1285. doi: 10.1136/bmj.g1285.</citation>
    <PMID>24513442</PMID>
  </reference>
  <reference>
    <citation>Phelan S, Phipps MG, Abrams B, Darroch F, Grantham K, Schaffner A, Wing RR. Does behavioral intervention in pregnancy reduce postpartum weight retention? Twelve-month outcomes of the Fit for Delivery randomized trial. Am J Clin Nutr. 2014 Feb;99(2):302-11. doi: 10.3945/ajcn.113.070151. Epub 2013 Nov 27.</citation>
    <PMID>24284438</PMID>
  </reference>
  <reference>
    <citation>Renault KM, Nrgaard K, Nilas L, Carlsen EM, Cortes D, Pryds O, Secher NJ. The Treatment of Obese Pregnant Women (TOP) study: a randomized controlled trial of the effect of physical activity intervention assessed by pedometer with or without dietary intervention in obese pregnant women. Am J Obstet Gynecol. 2014 Feb;210(2):134.e1-9. doi: 10.1016/j.ajog.2013.09.029. Epub 2013 Sep 20.</citation>
    <PMID>24060449</PMID>
  </reference>
  <reference>
    <citation>Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, Hayes L, Khazaezadeh N, Nelson SM, Oteng-Ntim E, Pasupathy D, Patel N, Robson SC, Sandall J, Sanders TA, Sattar N, Seed PT, Wardle J, Whitworth MK, Briley AL; UPBEAT Trial Consortium. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2015 Oct;3(10):767-77. doi: 10.1016/S2213-8587(15)00227-2. Epub 2015 Jul 9.</citation>
    <PMID>26165396</PMID>
  </reference>
  <reference>
    <citation>Sagedal LR, verby NC, Bere E, Torstveit MK, Lohne-Seiler H, Smstuen M, Hillesund ER, Henriksen T, Vistad I. Lifestyle intervention to limit gestational weight gain: the Norwegian Fit for Delivery randomised controlled trial. BJOG. 2017 Jan;124(1):97-109. doi: 10.1111/1471-0528.13862. Epub 2016 Jan 14.</citation>
    <PMID>26768233</PMID>
  </reference>
  <reference>
    <citation>Dodd JM, Grivell RM, Crowther CA, Robinson JS. Antenatal interventions for overweight or obese pregnant women: a systematic review of randomised trials. BJOG. 2010 Oct;117(11):1316-26. doi: 10.1111/j.1471-0528.2010.02540.x. Review.</citation>
    <PMID>20353459</PMID>
  </reference>
  <reference>
    <citation>Tanentsapf I, Heitmann BL, Adegboye AR. Systematic review of clinical trials on dietary interventions to prevent excessive weight gain during pregnancy among normal weight, overweight and obese women. BMC Pregnancy Childbirth. 2011 Oct 26;11:81. doi: 10.1186/1471-2393-11-81. Review.</citation>
    <PMID>22029725</PMID>
  </reference>
  <reference>
    <citation>Quinlivan JA, Julania S, Lam L. Antenatal dietary interventions in obese pregnant women to restrict gestational weight gain to Institute of Medicine recommendations: a meta-analysis. Obstet Gynecol. 2011 Dec;118(6):1395-401. doi: 10.1097/AOG.0b013e3182396bc6. Review.</citation>
    <PMID>22105270</PMID>
  </reference>
  <reference>
    <citation>Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, Kunz R, Mol BW, Coomarasamy A, Khan KS. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ. 2012 May 16;344:e2088. doi: 10.1136/bmj.e2088.</citation>
    <PMID>22596383</PMID>
  </reference>
  <reference>
    <citation>Thangaratinam S, Jolly K. Obesity in pregnancy: a review of reviews on the effectiveness of interventions. BJOG. 2010 Oct;117(11):1309-12. doi: 10.1111/j.1471-0528.2010.02670.x.</citation>
    <PMID>20862792</PMID>
  </reference>
  <reference>
    <citation>Kiel DW, Dodson EA, Artal R, Boehmer TK, Leet TL. Gestational weight gain and pregnancy outcomes in obese women: how much is enough? Obstet Gynecol. 2007 Oct;110(4):752-8.</citation>
    <PMID>17906005</PMID>
  </reference>
  <reference>
    <citation>Oken E, Kleinman KP, Belfort MB, Hammitt JK, Gillman MW. Associations of gestational weight gain with short- and longer-term maternal and child health outcomes. Am J Epidemiol. 2009 Jul 15;170(2):173-80. doi: 10.1093/aje/kwp101. Epub 2009 May 13.</citation>
    <PMID>19439579</PMID>
  </reference>
  <reference>
    <citation>Bodnar LM, Siega-Riz AM, Simhan HN, Himes KP, Abrams B. Severe obesity, gestational weight gain, and adverse birth outcomes. Am J Clin Nutr. 2010 Jun;91(6):1642-8. doi: 10.3945/ajcn.2009.29008. Epub 2010 Mar 31.</citation>
    <PMID>20357043</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Mele L, Landon MB, Ramin SM, Reddy UM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Saade G, Sorokin Y, Peaceman AM, Tolosa JE; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Inadequate weight gain in overweight and obese pregnant women: what is the effect on fetal growth? Am J Obstet Gynecol. 2014 Aug;211(2):137.e1-7. doi: 10.1016/j.ajog.2014.02.004. Epub 2014 Feb 11.</citation>
    <PMID>24530820</PMID>
  </reference>
  <reference>
    <citation>Wallace JM, Bhattacharya S, Campbell DM, Horgan GW. Inter-pregnancy weight change impacts placental weight and is associated with the risk of adverse pregnancy outcomes in the second pregnancy. BMC Pregnancy Childbirth. 2014 Jan 22;14:40. doi: 10.1186/1471-2393-14-40.</citation>
    <PMID>24450357</PMID>
  </reference>
  <reference>
    <citation>Jain AP, Gavard JA, Rice JJ, Catanzaro RB, Artal R, Hopkins SA. The impact of interpregnancy weight change on birthweight in obese women. Am J Obstet Gynecol. 2013 Mar;208(3):205.e1-7. doi: 10.1016/j.ajog.2012.12.018. Epub 2012 Dec 12.</citation>
    <PMID>23246318</PMID>
  </reference>
  <reference>
    <citation>Ehrlich SF, Hedderson MM, Feng J, Davenport ER, Gunderson EP, Ferrara A. Change in body mass index between pregnancies and the risk of gestational diabetes in a second pregnancy. Obstet Gynecol. 2011 Jun;117(6):1323-30. doi: 10.1097/AOG.0b013e31821aa358.</citation>
    <PMID>21606742</PMID>
  </reference>
  <reference>
    <citation>Mostello D, Jen Chang J, Allen J, Luehr L, Shyken J, Leet T. Recurrent preeclampsia: the effect of weight change between pregnancies. Obstet Gynecol. 2010 Sep;116(3):667-72. doi: 10.1097/AOG.0b013e3181ed74ea.</citation>
    <PMID>20733450</PMID>
  </reference>
  <reference>
    <citation>Getahun D, Ananth CV, Oyelese Y, Chavez MR, Kirby RS, Smulian JC. Primary preeclampsia in the second pregnancy: effects of changes in prepregnancy body mass index between pregnancies. Obstet Gynecol. 2007 Dec;110(6):1319-25.</citation>
    <PMID>18055727</PMID>
  </reference>
  <reference>
    <citation>Bogaerts A, Van den Bergh BR, Ameye L, Witters I, Martens E, Timmerman D, Devlieger R. Interpregnancy weight change and risk for adverse perinatal outcome. Obstet Gynecol. 2013 Nov;122(5):999-1009. doi: 10.1097/AOG.0b013e3182a7f63e.</citation>
    <PMID>24104777</PMID>
  </reference>
  <reference>
    <citation>Glazer NL, Hendrickson AF, Schellenbaum GD, Mueller BA. Weight change and the risk of gestational diabetes in obese women. Epidemiology. 2004 Nov;15(6):733-7.</citation>
    <PMID>15475723</PMID>
  </reference>
  <reference>
    <citation>Lovelady CA, Garner KE, Moreno KL, Williams JP. The effect of weight loss in overweight, lactating women on the growth of their infants. N Engl J Med. 2000 Feb 17;342(7):449-53.</citation>
    <PMID>10675424</PMID>
  </reference>
  <reference>
    <citation>Colleran HL, Lovelady CA. Use of MyPyramid Menu Planner for Moms in a weight-loss intervention during lactation. J Acad Nutr Diet. 2012 Apr;112(4):553-8. doi: 10.1016/j.jand.2011.12.004.</citation>
    <PMID>22709705</PMID>
  </reference>
  <reference>
    <citation>Stendell-Hollis NR, Thompson PA, West JL, Wertheim BC, Thomson CA. A comparison of Mediterranean-style and MyPyramid diets on weight loss and inflammatory biomarkers in postpartum breastfeeding women. J Womens Health (Larchmt). 2013 Jan;22(1):48-57. doi: 10.1089/jwh.2012.3707. Epub 2012 Dec 31.</citation>
    <PMID>23276189</PMID>
  </reference>
  <reference>
    <citation>O'Toole ML, Sawicki MA, Artal R. Structured diet and physical activity prevent postpartum weight retention. J Womens Health (Larchmt). 2003 Dec;12(10):991-8.</citation>
    <PMID>14709187</PMID>
  </reference>
  <reference>
    <citation>Nascimento SL, Pudwell J, Surita FG, Adamo KB, Smith GN. The effect of physical exercise strategies on weight loss in postpartum women: a systematic review and meta-analysis. Int J Obes (Lond). 2014 May;38(5):626-35. doi: 10.1038/ijo.2013.183. Epub 2013 Sep 19. Review.</citation>
    <PMID>24048142</PMID>
  </reference>
  <reference>
    <citation>Rn K, Stach-Lempinen B, Klemetti MM, Kaaja RJ, Pyhnen-Alho M, Eriksson JG, Koivusalo SB; RADIEL group. Prevention of gestational diabetes through lifestyle intervention: study design and methods of a Finnish randomized controlled multicenter trial (RADIEL). BMC Pregnancy Childbirth. 2014 Feb 14;14:70. doi: 10.1186/1471-2393-14-70.</citation>
    <PMID>24524674</PMID>
  </reference>
  <reference>
    <citation>Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet. 2006 Sep 30;368(9542):1164-70.</citation>
    <PMID>17011943</PMID>
  </reference>
  <reference>
    <citation>Lassance L, Haghiac M, Leahy P, Basu S, Minium J, Zhou J, Reider M, Catalano PM, Hauguel-de Mouzon S. Identification of early transcriptome signatures in placenta exposed to insulin and obesity. Am J Obstet Gynecol. 2015 May;212(5):647.e1-11. doi: 10.1016/j.ajog.2015.02.026. Epub 2015 Feb 28.</citation>
    <PMID>25731694</PMID>
  </reference>
  <reference>
    <citation>Yassine HN, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults--a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009 Jan;64(1):90-5. doi: 10.1093/gerona/gln032. Epub 2009 Jan 20.</citation>
    <PMID>19164269</PMID>
  </reference>
  <reference>
    <citation>Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines; Rasmussen KM, Yaktine AL, editors. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington (DC): National Academies Press (US); 2009.</citation>
    <PMID>20669500</PMID>
  </reference>
  <reference>
    <citation>Resi V, Basu S, Haghiac M, Presley L, Minium J, Kaufman B, Bernard S, Catalano P, Hauguel-de Mouzon S. Molecular inflammation and adipose tissue matrix remodeling precede physiological adaptations to pregnancy. Am J Physiol Endocrinol Metab. 2012 Oct 1;303(7):E832-40. doi: 10.1152/ajpendo.00002.2012. Epub 2012 Jul 17.</citation>
    <PMID>22811467</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol. 1991 Dec;165(6 Pt 1):1667-72.</citation>
    <PMID>1750458</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Tyzbir ED, Wolfe RR, Roman NM, Amini SB, Sims EA. Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion in normal pregnant women. Am J Obstet Gynecol. 1992 Oct;167(4 Pt 1):913-9.</citation>
    <PMID>1415425</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, Sims EA. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol. 1993 Jan;264(1 Pt 1):E60-7.</citation>
    <PMID>8430789</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Drago NM, Amini SB. Factors affecting fetal growth and body composition. Am J Obstet Gynecol. 1995 May;172(5):1459-63.</citation>
    <PMID>7755054</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Drago NM, Amini SB. Maternal carbohydrate metabolism and its relationship to fetal growth and body composition. Am J Obstet Gynecol. 1995 May;172(5):1464-70.</citation>
    <PMID>7755055</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Roman-Drago NM, Amini SB, Sims EA. Longitudinal changes in body composition and energy balance in lean women with normal and abnormal glucose tolerance during pregnancy. Am J Obstet Gynecol. 1998 Jul;179(1):156-65.</citation>
    <PMID>9704782</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 1999 Apr;180(4):903-16.</citation>
    <PMID>10203659</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Nizielski SE, Shao J, Preston L, Qiao L, Friedman JE. Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: relationship to FFA during pregnancy. Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E522-33.</citation>
    <PMID>11832353</PMID>
  </reference>
  <reference>
    <citation>O'Tierney-Ginn P, Presley L, Myers S, Catalano P. Placental growth response to maternal insulin in early pregnancy. J Clin Endocrinol Metab. 2015 Jan;100(1):159-65. doi: 10.1210/jc.2014-3281.</citation>
    <PMID>25365315</PMID>
  </reference>
  <reference>
    <citation>Koontz MB, Gunzler DD, Presley L, Catalano PM. Longitudinal changes in infant body composition: association with childhood obesity. Pediatr Obes. 2014 Dec;9(6):e141-4. doi: 10.1111/ijpo.253. Epub 2014 Sep 30.</citation>
    <PMID>25267097</PMID>
  </reference>
  <reference>
    <citation>Kirwan JP, Varastehpour A, Jing M, Presley L, Shao J, Friedman JE, Catalano PM. Reversal of insulin resistance postpartum is linked to enhanced skeletal muscle insulin signaling. J Clin Endocrinol Metab. 2004 Sep;89(9):4678-84.</citation>
    <PMID>15356080</PMID>
  </reference>
  <reference>
    <citation>Friedman JE, Kirwan JP, Jing M, Presley L, Catalano PM. Increased skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum. Diabetes. 2008 Mar;57(3):606-13. Epub 2007 Dec 14.</citation>
    <PMID>18083784</PMID>
  </reference>
  <reference>
    <citation>Solomon TP, Haus JM, Kelly KR, Rocco M, Kashyap SR, Kirwan JP. Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care. 2010 Jul;33(7):1561-6. doi: 10.2337/dc09-2021. Epub 2010 Mar 3.</citation>
    <PMID>20200305</PMID>
  </reference>
  <reference>
    <citation>Solomon TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M, Kashyap SR, Watanabe RM, Barkoukis H, Kirwan JP. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr. 2010 Dec;92(6):1359-68. doi: 10.3945/ajcn.2010.29771. Epub 2010 Oct 27.</citation>
    <PMID>20980494</PMID>
  </reference>
  <reference>
    <citation>Calabuig-Navarro V, Puchowicz M, Glazebrook P, Haghiac M, Minium J, Catalano P, Hauguel deMouzon S, O'Tierney-Ginn P. Effect of -3 supplementation on placental lipid metabolism in overweight and obese women. Am J Clin Nutr. 2016 Apr;103(4):1064-72.</citation>
    <PMID>26961929</PMID>
  </reference>
  <reference>
    <citation>Ptomey LT, Willis EA, Honas JJ, Mayo MS, Washburn RA, Herrmann SD, Sullivan DK, Donnelly JE. Validity of energy intake estimated by digital photography plus recall in overweight and obese young adults. J Acad Nutr Diet. 2015 Sep;115(9):1392-9. doi: 10.1016/j.jand.2015.05.006. Epub 2015 Jun 26.</citation>
    <PMID>26122282</PMID>
  </reference>
  <reference>
    <citation>Look AHEAD Research Group, Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, Williamson D, Berkowitz RI, Kelley DE, Tomchee C, Hill JO, Kumanyika S. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006 May;14(5):737-52. Review. Erratum in: Obesity (Silver Spring). 2007 May;15(5):1339. Wadden, Thomas A [added]; West, Delia Smith [added]; Delahanty, Linda [added]; Jakicic, John [added]; Rejeski, Jack [added]; Williamson, Don [added]; Berkowitz, Robert I [added]; Kelley, David E [added]; Tomchee, Christine [added]; Hill, James O [added]; K.</citation>
    <PMID>16855180</PMID>
  </reference>
  <reference>
    <citation>Donnelly JE, Goetz J, Gibson C, Sullivan DK, Lee R, Smith BK, Lambourne K, Mayo MS, Hunt S, Lee JH, Honas JJ, Washburn RA. Equivalent weight loss for weight management programs delivered by phone and clinic. Obesity (Silver Spring). 2013 Oct;21(10):1951-9. doi: 10.1002/oby.20334. Epub 2013 May 25.</citation>
    <PMID>23408579</PMID>
  </reference>
  <reference>
    <citation>Siri WE. Body composition from fluid spaces and density: analysis of methods. 1961. Nutrition. 1993 Sep-Oct;9(5):480-91; discussion 480, 492.</citation>
    <PMID>8286893</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Wong WW, Drago NM, Amini SB. Estimating body composition in late gestation: a new hydration constant for body density and total body water. Am J Physiol. 1995 Jan;268(1 Pt 1):E153-8.</citation>
    <PMID>7840173</PMID>
  </reference>
  <reference>
    <citation>Sady SP, Carpenter MW, Sady MA, Haydon B, Hoegsberg B, Cullinane EM, Thompson PD, Coustan DR. Prediction of VO2max during cycle exercise in pregnant women. J Appl Physiol (1985). 1988 Aug;65(2):657-61.</citation>
    <PMID>3170418</PMID>
  </reference>
  <reference>
    <citation>Watanabe RM, Steil GM, Bergman RN. Critical evaluation of the combined model approach for estimation of prehepatic insulin secretion. Am J Physiol. 1998 Jan;274(1):E172-83. doi: 10.1152/ajpendo.1998.274.1.E172.</citation>
    <PMID>9458763</PMID>
  </reference>
  <reference>
    <citation>Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982 Dec 1;144(7):768-73.</citation>
    <PMID>7148898</PMID>
  </reference>
  <reference>
    <citation>Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care. 1994 Apr;17(4):267-74.</citation>
    <PMID>8026281</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998 Nov;51(11):903-12.</citation>
    <PMID>9817107</PMID>
  </reference>
  <reference>
    <citation>Sewell MF, Huston-Presley L, Super DM, Catalano P. Increased neonatal fat mass, not lean body mass, is associated with maternal obesity. Am J Obstet Gynecol. 2006 Oct;195(4):1100-3. Epub 2006 Jul 26.</citation>
    <PMID>16875645</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Tyzbir ED, Allen SR, McBean JH, McAuliffe TL. Evaluation of fetal growth by estimation of neonatal body composition. Obstet Gynecol. 1992 Jan;79(1):46-50.</citation>
    <PMID>1727584</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Thomas AJ, Avallone DA, Amini SB. Anthropometric estimation of neonatal body composition. Am J Obstet Gynecol. 1995 Oct;173(4):1176-81.</citation>
    <PMID>7485315</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Presley L, Minium J, Hauguel-de Mouzon S. Fetuses of obese mothers develop insulin resistance in utero. Diabetes Care. 2009 Jun;32(6):1076-80. doi: 10.2337/dc08-2077.</citation>
    <PMID>19460915</PMID>
  </reference>
  <reference>
    <citation>Lindsay CA, Thomas AJ, Catalano PM. The effect of smoking tobacco on neonatal body composition. Am J Obstet Gynecol. 1997 Nov;177(5):1124-8.</citation>
    <PMID>9396906</PMID>
  </reference>
  <reference>
    <citation>Rohl J, Huston-Presley L, Amini S, Stepanchak B, Catalano P. Factors associated with fetal growth and body composition as measured by ultrasound. Am J Obstet Gynecol. 2001 Dec;185(6):1416-20.</citation>
    <PMID>11744918</PMID>
  </reference>
  <reference>
    <citation>Hashimoto K, Wong WW, Thomas AJ, Uvena-Celebrezze J, Huston-Pressley L, Amini SB, Catalano PM. Estimation of neonatal body composition: isotope dilution versus total-body electrical conductivity. Biol Neonate. 2002;81(3):170-5.</citation>
    <PMID>11937722</PMID>
  </reference>
  <reference>
    <citation>Uvena-Celebrezze J, Fung C, Thomas AJ, Hoty A, Huston-Presley L, Amini SB, Catalano PM. Relationship of neonatal body composition to maternal glucose control in women with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2002 Dec;12(6):396-401.</citation>
    <PMID>12683650</PMID>
  </reference>
  <reference>
    <citation>Catalano PM, Thomas A, Huston-Presley L, Amini SB. Increased fetal adiposity: a very sensitive marker of abnormal in utero development. Am J Obstet Gynecol. 2003 Dec;189(6):1698-704.</citation>
    <PMID>14710101</PMID>
  </reference>
  <reference>
    <citation>Durnwald C, Huston-Presley L, Amini S, Catalano P. Evaluation of body composition of large-for-gestational-age infants of women with gestational diabetes mellitus compared with women with normal glucose tolerance levels. Am J Obstet Gynecol. 2004 Sep;191(3):804-8.</citation>
    <PMID>15467545</PMID>
  </reference>
  <reference>
    <citation>Singh KA, Huston-Presley LP, Mencin P, Thomas A, Amini SB, Catalano PM. Birth weight and body composition of neonates born to Caucasian compared with African-American mothers. Obstet Gynecol. 2010 May;115(5):998-1002. doi: 10.1097/AOG.0b013e3181da901a.</citation>
    <PMID>20410774</PMID>
  </reference>
  <reference>
    <citation>Waters TP, Huston-Presley L, Catalano PM. Neonatal body composition according to the revised institute of medicine recommendations for maternal weight gain. J Clin Endocrinol Metab. 2012 Oct;97(10):3648-54. doi: 10.1210/jc.2012-1781. Epub 2012 Jul 20.</citation>
    <PMID>22821895</PMID>
  </reference>
  <reference>
    <citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.</citation>
    <PMID>3899825</PMID>
  </reference>
  <reference>
    <citation>Lassance L, Haghiac M, Minium J, Catalano P, Hauguel-de Mouzon S. Obesity-induced down-regulation of the mitochondrial translocator protein (TSPO) impairs placental steroid production. J Clin Endocrinol Metab. 2015 Jan;100(1):E11-8. doi: 10.1210/jc.2014-2792.</citation>
    <PMID>25322273</PMID>
  </reference>
  <reference>
    <citation>Visiedo F, Bugatto F, Snchez V, Czar-Castellano I, Bartha JL, Perdomo G. High glucose levels reduce fatty acid oxidation and increase triglyceride accumulation in human placenta. Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E205-12. doi: 10.1152/ajpendo.00032.2013. Epub 2013 May 14.</citation>
    <PMID>23673156</PMID>
  </reference>
  <reference>
    <citation>Brass E, Hanson E, O'Tierney-Ginn PF. Placental oleic acid uptake is lower in male offspring of obese women. Placenta. 2013 Jun;34(6):503-9. doi: 10.1016/j.placenta.2013.03.009. Epub 2013 Apr 17.</citation>
    <PMID>23602336</PMID>
  </reference>
  <reference>
    <citation>Hughes SD, Quaade C, Johnson JH, Ferber S, Newgard CB. Transfection of AtT-20ins cells with GLUT-2 but not GLUT-1 confers glucose-stimulated insulin secretion. Relationship to glucose metabolism. J Biol Chem. 1993 Jul 15;268(20):15205-12.</citation>
    <PMID>8325893</PMID>
  </reference>
  <reference>
    <citation>FOLCH J, LEES M, SLOANE STANLEY GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497-509.</citation>
    <PMID>13428781</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>overweight</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>fetal growth/adiposity</keyword>
  <keyword>Mediterranean diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Macrosomia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results of the study will be available in a de-identified manner by contacting the Principal Investigator, after the results have been published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

